Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Approves MPS VI Drug Naglzayme

This article was originally published in PharmAsia News

Executive Summary

Osaka-based Anges MG announced that mucopolysaccharidosis VI drug Naglazyme (galsulfase) received manufacturing and marketing approval by Japan's Ministry of Health, Labor and Welfare March 28, three days after it cleared MHLW's drug review panel. The ministry considers Naglazyme the only effective treatment for MPS VI. A severe and progressive genetic disease, MPS is caused by an enzyme deficiency, which leads to progressive organ system dysfunction. Naglazyme has been available in Europe and the U.S and was designated as an orphan drug last June. The NHI price listing will take place in April 18. Anges MG obtained developing and marketing rights in Japan from California-based BioMarin. (Click here for more - Japanese language

You may also be interested in...

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts